IDX-184

IDX-184 is an experimental antiviral drug that was developed by Idenix Pharmaceuticals for the treatment of Hepatitis C. It is a nucleotide analogue, specifically a prodrug of 2'-methylguanosine monophosphate, which acts as an inhibitor of the Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, an essential enzyme for the replication of the virus.

History[edit | edit source]

IDX-184 was first synthesized and studied by Idenix Pharmaceuticals, a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of human viral diseases. The drug entered Phase I clinical trials in 2007, and Phase II trials in 2010. However, in 2013, the U.S. Food and Drug Administration (FDA) placed IDX-184 on clinical hold due to safety concerns, effectively halting further development.

Mechanism of Action[edit | edit source]

As a nucleotide analogue, IDX-184 is metabolized in the liver to its active form, 2'-methylguanosine triphosphate. This active form inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing the replication of the virus. This mechanism of action is similar to that of other nucleotide analogues used in the treatment of HCV, such as Sofosbuvir.

Clinical Trials[edit | edit source]

In Phase I clinical trials, IDX-184 was found to be generally well-tolerated, with the most common side effects being mild to moderate in severity. In Phase II trials, the drug demonstrated potent antiviral activity, with a significant reduction in HCV RNA levels observed in patients treated with IDX-184.

However, in 2013, the FDA placed IDX-184 on clinical hold due to safety concerns. This decision was based on reports of serious cardiac events in patients treated with another nucleotide analogue, BMS-986094, which is structurally similar to IDX-184. Despite the clinical hold, no such events were reported in the clinical trials of IDX-184.

Future Development[edit | edit source]

Following the FDA's decision, Idenix Pharmaceuticals halted further development of IDX-184. The future of the drug is currently uncertain, with no plans announced for its resumption.